Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.44 |
| ▸ | PPARA | Q07869 | 4/20 | 0.44 |
| ▸ | F7 | P08709 | 3/20 | 0.44 |
| ▸ | F3 | P13726 | 3/20 | 0.44 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | OXER1 | Q8TDS5 | 3/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | RXRA | P19793 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4073056 | 1.00 | EPHX2 (0.50) | EPHX2ALDH1A1CYP19A1PPARAF7 | |
| SCHEMBL4076228 | 1.00 | EPHX2 (0.50) | EPHX2ALDH1A1CYP19A1PPARAF7 | |
| SCHEMBL8072218 | 0.91 | EPHX2 (0.60) | EPHX2ALDH1A1CYP19A1PPARAF7 | |
| SCHEMBL8072057 | 0.91 | EPHX2 (0.60) | EPHX2ALDH1A1CYP19A1PPARAF7 | |
| SCHEMBL17784473 | 0.86 | EPHX2 (0.54) | EPHX2PPARAAPPFAAH | |
| SCHEMBL9777764 | 0.86 | EPHX2 (0.54) | EPHX2PPARAAPPFAAH | |
| SCHEMBL9777768 | 0.86 | EPHX2 (0.54) | EPHX2PPARAAPPFAAH | |
| SCHEMBL28517631 | 0.86 | ALDH1A1 (0.56) | EPHX2ALDH1A1CYP19A1PPARAF7 | |
| SCHEMBL4082941 | 0.86 | ALDH1A1 (0.56) | EPHX2ALDH1A1CYP19A1PPARAF7 | |
| SCHEMBL10978361 | 0.86 | EPHX2 (0.41) | EPHX2ALDH1A1CYP19A1PPARAF7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160256567-A1 | COMPOSITIONS AND METHODS FOR DELIVERING MESSENGER RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2016-09-08 | — | — | US | disclosed |
| US-9206206-B2 | Oxidized lipid compounds and uses thereof | VASCULAR BIOGENICS LTD. (IL) | 2015-12-08 | — | — | US | disclosed |
| CN-104788492-A | Oxidized lipid compounds and uses thereof | VASCULAR BIOGENICS LTD | 2015-07-22 | — | — | CN | disclosed |
| CN-102271517-B | Oxidized lipid compounds and uses thereof | VASCULAR BIOGENICS LTD | 2015-04-08 | — | — | CN | disclosed |
| EP-2826369-A2 | Oxidized lipid compounds and uses thereof | Vascular Biogenics Ltd. (IL) | 2015-01-21 | — | — | EP | disclosed |
| EP-2826370-A2 | Oxidized lipid compounds and uses thereof | Vascular Biogenics Ltd. (IL) | 2015-01-21 | — | — | EP | disclosed |
| EP-2348866-B1 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | VASCULAR BIOGENICS LTD (IL) | 2015-01-07 | — | — | EP | disclosed |
| US-20130203707-A1 | Oxidized Lipid Compounds and Uses Thereof | VASCULAR BIOGENICS LTD. (IL) | 2013-08-08 | — | — | US | disclosed |
| CN-102271517-A | oxidized lipid compounds and uses thereof | — | 2011-12-07 | — | — | CN | disclosed |
| US-20110207703-A1 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | VASCULAR BIOGENICS LTD. (IL) | 2011-08-25 | — | — | US | disclosed |
| EP-2348866-A1 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | Vascular Biogenics Ltd. (IL) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010052718-A9 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | VASCULAR BIOGENICS LTD. (IL) | 2011-06-16 | — | — | WO | disclosed |
| WO-2010052718-A1 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | VASCULAR BIOGENICS LTD. (IL) | 2010-05-14 | — | — | WO | disclosed |
| US-7488748-B2 | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-10 | — | — | US | disclosed |
| US-20060247225-A1 | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-02 | — | — | US | disclosed |
| EP-1590325-A1 | 3,6-DISUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004067510-A1 | 3,6-DISUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160256567-A1 | COMPOSITIONS AND METHODS FOR DELIVERING MESSENGER RNA | NSUN3, RNMT, RNASE1 | EPHX2 2335/4885ALDH1A1 4469/4885CYP19A1 3651/4885 |
| US-20060247225-A1 | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | EPHX2 406/4885ALDH1A1 1292/4885CYP19A1 1534/4885 |
| US-20130203707-A1 | Oxidized Lipid Compounds and Uses Thereof | LPO, GPX4, ALOX15B | EPHX2 380/4885ALDH1A1 616/4885CYP19A1 797/4885 |
| US-20110207703-A1 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | LPO, GPX4, ALOX15B | EPHX2 380/4885ALDH1A1 616/4885CYP19A1 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.